CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $5.17M, lower than 95% of all stocks globally
- PositionPrice-to-book is 18.31×, higher than 95% of its Biotechnology peers (median 2.86×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.81BCNY867.55M · vs all stocks (USD)
Revenue (TTM)
34.67MCNY5.17M · vs all stocks (USD)
Profit Margin
-246.69%vs Biotechnology peers
Beta
0.6690xvs all stocks
52-Week Change
-19.06%vs all stocks
Market Capitalization
5.81BCNY867.55M · vs all stocks (USD)
Enterprise Value
4.63BCNY691.20M · vs all stocks (USD)
Price to Book (MRQ)
18.31xvs Biotechnology peers
Enterprise to Revenue
133.57xvs Biotechnology peers
Enterprise to EBITDA
-29.20xvs Biotechnology peers
Profit Margin
-246.69%vs Biotechnology peers
Operating Margin
-464.35%vs Biotechnology peers
Return on Assets (TTM)
-13.02%vs Biotechnology peers
Return on Equity (TTM)
-12.92%vs Biotechnology peers
Revenue (TTM)
34.67MCNY5.17M · vs all stocks (USD)
Revenue per Share (TTM)
0.2340CNYUpdated Sep 22, 2026Quarterly Revenue Growth
-100.00%vs Biotechnology peers
Gross Profit (TTM)
34.40MCNY5.14M · vs all stocks (USD)
EBITDA (TTM)
-158.60MCNY-23.67M · vs all stocks (USD)
Net Income (TTM)
-85.52MCNY-12.77M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-100.00%vs Biotechnology peers
Operating Cash Flow (TTM)
-110.80MCNY-16.54M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-116.63MCNY-17.41M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
8.67MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
266.10KCNYFY2025 · Dec 31, 2025Gross Profit
8.40MCNYFY2025 · Dec 31, 2025Operating Income
-146.43MCNY-21.86M · vs all stocks (USD)
Pre-tax Income
-128.83MCNYFY2025 · Dec 31, 2025Net Income
-128.83MCNYFY2025 · Dec 31, 2025EBIT
-128.70MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-128.65MCNYFY2025 · Dec 31, 2025Research & Development
196.70MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
6.35MCNYFY2025 · Dec 31, 2025Other Operating Expenses
46.42KCNYFY2025 · Dec 31, 2025Non-operating Interest Income
664.19KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
133.13KCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.8700CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.8700CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
148.09MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
148.09MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-128.83MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-141.41MCNYFY2025 · Dec 31, 2025Free Cash Flow
-144.61MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
17.59MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-128.83MCNYFY2025 · Dec 31, 2025Other Non-cash Items
778.59KCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-13.68MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
329.63KCNYFY2025 · Dec 31, 2025Capital Expenditures
-3.20MCNYFY2025 · Dec 31, 2025Purchase of Investments
-3.01BCNYFY2025 · Dec 31, 2025Sale of Investments
3.18BCNYFY2025 · Dec 31, 2025Other Investing Activity
-15.94MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
157.48MCNYFY2025 · Dec 31, 2025Other Financing Charges
-4.79MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-4.79MCNYFY2025 · Dec 31, 2025Shares Outstanding
148.72MSharesUpdated Sep 22, 2026Float Shares
55.50MSharesUpdated Sep 22, 2026% Held by Insiders
72.31%vs all stocks
% Held by Institutions
7.15%vs all stocks
Total Cash (MRQ)
626.10MCNY93.46M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.21CNYUpdated Sep 22, 2026Total Debt (MRQ)
8.34MCNY1.24M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0135xvs Biotechnology peers
Current Ratio (MRQ)
6.51xvs Biotechnology peers
Book Value per Share (MRQ)
2.08CNYUpdated Sep 22, 2026Total Assets
791.23MCNY118.11M · vs all stocks (USD)
Total Current Assets
704.84MCNYFY2025 · Dec 31, 2025Total Liabilities
111.05MCNYFY2025 · Dec 31, 2025Total Non-current Assets
86.39MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
8.92MCNYFY2025 · Dec 31, 2025Total Current Liabilities
102.14MCNYFY2025 · Dec 31, 2025Cash
17.59MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
17.59MCNYFY2025 · Dec 31, 2025Other Short-term Investments
654.26MCNYFY2025 · Dec 31, 2025Accounts Receivable
331.67KCNYFY2025 · Dec 31, 2025Inventory
3.08MCNYFY2025 · Dec 31, 2025Accounts Payable
88.53MCNYFY2025 · Dec 31, 2025Short-term Debt
4.77MCNYFY2025 · Dec 31, 2025Long-term Debt
8.86MCNYFY2025 · Dec 31, 2025Common Stock (Book)
148.72MCNYFY2025 · Dec 31, 2025Retained Earnings
-1.15BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
680.18MCNY101.53M · vs all stocks (USD)
52-Week Low
29.71CNYUpdated Sep 22, 202652-Week High
48.97CNYUpdated Sep 22, 202652-Week Change
-19.06%vs all stocks
Beta
0.6690xvs all stocks
50-Day MA
35.21CNYUpdated Sep 22, 2026200-Day MA
37.17CNYUpdated Sep 22, 2026Avg 10-Day Volume
2.29MSharesUpdated Sep 22, 2026Avg 30-Day Volume
2.60MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
-0.5800CNYUpdated Sep 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 18.31×, higher than 95% of its Biotechnology peers (median 2.86×)Significant
Price-to-book: 18.31Industry median: 2.86Industry P95: 13.08Peers compared: 260
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $5.17M, lower than 95% of all stocks globallySignificant
Revenue (USD): 5,174,829.07Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Guizhou Sanli Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Wuhan Keqian Biology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chongqing Pharscin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hpgc Renmintongtai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Wanbangde Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing SL Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Bio-Sincerity Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sana Biotechnology, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Ardelyx Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kuros Biosciences AG
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking